Navigation Links
First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes

-- Additional Findings Reported on Glucose Homeostasis Effects in Normal and Diabetic Rats --

CHICAGO, June 25, 2007 /PRNewswire-FirstCall/ -- In a 14-day, Phase IIa study of the safety profile of multiple doses of the investigational compound dapagliflozin, a selective inhibitor of the Sodium-Glucose Transporter 2 (SGLT2) administered alone or concomitantly with metformin in subjects with Type 2 diabetes, no discontinuations due to adverse events and no serious adverse events were reported. The study, presented this week at the annual meeting of the American Diabetes Association, also reported that dapagliflozin, in development by Bristol-Myers Squibb Company and AstraZeneca , statistically significantly reduced fasting serum glucose (FSG) and post challenge glucose excursion in subjects with Type 2 diabetes.

The data were from a double-blind, placebo-controlled, randomized, parallel-group study of 47 subjects with an established diagnosis of Type 2 diabetes (ages 18-77) who were either drug-naive or on a stable dose of metformin for at least 4 weeks prior to randomization with hemoglobin A1C levels between 6 and 10 percent with a FSG of less than or equal to 240 mg/dL. Subjects were randomized to receive either placebo (n=8) or dapagliflozin 5 mg (n=11), 25 mg (n=12), or 100 mg (n=16) once daily for 14 days in addition to their stable metformin dose and/or diet alone in an in-patient clinical research unit. The primary endpoint of the study was to assess both the safety and tolerability profiles of multiple doses of dapagliflozin in subjects with Type 2 diabetes. The secondary endpoints of the study included assessing the fasting serum glucose and post challenge glucose excursion. The presentation, "Dapagliflozin, a Selective Inhibitor of the Sodium-Glucose Uptake Transporter 2 (SGLT2), Reduces Fasting Serum Glucose and Glucose Excursion in Type 2 Diabetes Mellitus Patients Over 14 Days", was presented by Bernard Komoroski, PharmD, Ph.D., Senior Research
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
7. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
8. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
9. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
10. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
11. Dasatinib Shows High Early Response Rate as First Treatment for Chronic Myelogenous Leukemia, M. D. Anderson Researchers Report
Post Your Comments:
(Date:5/22/2013)... ALEXANDRIA, Va. , May 22, 2013  Viral hepatitis ... More than 75 percent of those with hepatitis C are ... and C Testing and Awareness Day in the U.S. House ... pm in the Rayburn Foyer of the Rayburn House Office ... The American Association for the Study of Liver Diseases ...
(Date:5/22/2013)... WHITE PLAINS, N.Y. , May 22, 2013 /PRNewswire/ ... $6 million to Valor Biotherapeutics, LLC, a ... completion of pre-clinical development, manufacturing, and a Phase I ... change the poor outcomes faced by many patients with ... with rituximab. Valor,s protein, IGN002, is ...
(Date:5/22/2013)... CAESAREA, Israel , May 22, 2013 ... clinical data presented from the DEFLECT-I study demonstrates that ... brain lesion volume during TAVR (Transcatheter Aortic Valve Replacement) ... Heart Scientific Advisory Board announces consensus on the importance ... the importance and need for cerebral protection during cardiovascular ...
Breaking Medicine Technology:Hepatitis Awareness: Bringing Attention to a Silent Epidemic 2The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 2The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 3The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 4New Clinical Data Presented at EuroPCR Demonstrates that TriGuard Reduces Brain Lesion Volume during TAVR 2New Clinical Data Presented at EuroPCR Demonstrates that TriGuard Reduces Brain Lesion Volume during TAVR 3New Clinical Data Presented at EuroPCR Demonstrates that TriGuard Reduces Brain Lesion Volume during TAVR 4
... Sept. 13 COPAN announced this week that it ... flocked swabs, FLOQSwabs, for collection and transfer of biological ... latest addition to a growing number of patents held ... flocked swabs for collection and transfer of biological samples, ...
... "Dan Rather Reports" will present an investigation into the ... drugs like Viagra or Cialis, these are counterfeit versions ... treatment of Alzheimer,s and Casodex, used to treat prostate ... for criminals while, potentially robbing unsuspecting victims of something ...
Cached Medicine Technology:COPAN Secures Japanese Patent for its Flocked Swab Innovation 2Are the Prescription Drugs You Are Taking Real, or Counterfeit? HDNet's Dan Rather Reports Investigates 2Are the Prescription Drugs You Are Taking Real, or Counterfeit? HDNet's Dan Rather Reports Investigates 3Are the Prescription Drugs You Are Taking Real, or Counterfeit? HDNet's Dan Rather Reports Investigates 4Are the Prescription Drugs You Are Taking Real, or Counterfeit? HDNet's Dan Rather Reports Investigates 5
(Date:5/23/2013)... (PRWEB) May 23, 2013 Ezell Law ... in practice. For 25 years, Jeff Ezell has ... advice with a focus on personal injury cases ... worked for insurance companies, he offers clients a uniquely ... companies operate, which enables him better serve his clients. ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Greenville ... that all team members and doctors have recently ... professional rescuer with an Automated External Defibrillator (AED). ... (AED) is a medical device designed to analyze ... to victims of ventricular fibrillation to restore the ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 OnSomble, Inc. ... nurse understanding of the professional role and empower nurses ... Joy, vice president of patient care services and chief ... nurses are excellent clinicians, and we want to help ... them that to lead they must follow, encourage them ...
(Date:5/23/2013)... Better Life Maids of Portland Oregon is putting ... its one of a kind green house cleaning service in ... completed May 29th, and a soft opening scheduled for June ... training in Portland recently and will travel to St. Louis ... "It really is a lot to take in" stated Heather ...
(Date:5/23/2013)... PhD Box has introduced a ... the research process by offering assistance for Thesis Proposals. The ... of services that the company provides for research consultation in ... dedicated proposal writing service is that this is the stage ... research process find it difficult to draft a proposal as ...
Breaking Medicine News(10 mins):Health News:Ezell Law Firm Celebrates 25 Years in Practice 2Health News:Greenville Oral & Maxillofacial Surgeons Announce CPR Re-Certification 2Health News:OnSomble, Inc. Partners with The Aroostook Medical Center to Enhance Nurse Understanding of the Professional Role 2Health News:Better Life Maids of Portland Oregon Prepares For a Summer of 2013 Launch 2Health News:PhD Box Unveils Proposal Writing Services for Research Scholars 2
... ... that wish to host continuing medical education courses at their medical facility in 2010. This ... well as reduce their overall costs to educate their physical therapy and occupational therapy team ... ...
... OAKLAND, Calif., Dec. 4 Herpes zoster, also known as ... against chicken pox, according to a Kaiser Permanente study in ... , The study, the largest of its kind, used ... with the varicella (chicken pox) vaccine from 2002 to 2008 ...
... Dec. 3 The Cancer Center at Harrington ... announced today. , "We expect to start seeing patients immediately," ... , The approval was granted today by the Massachusetts Department ... the facility. , The opening of The Cancer Center ...
... , CHICAGO, Dec. 3 ... United States District Court for the Southern District of ... disclosed $350 million settlement that would resolve a class-action ... the AMA, Medical Society of the State of New ...
... outperforms widely used sulfonylureas, but each patient will be different, ... A class of drugs still taken by millions of people ... of dying and heart failure than the newer treatment metformin, ... diabetes treatment, performed less well than metformin in a study ...
... ... ... nasal vaccines and H1N1 vaccine shots at four Centegra Primary Care (CPC) vaccination clinics ... Crystal Lake and McHenry and will be open as follows: ,   ...
Cached Medicine News:Health News:North American Seminars Inc. Opens Its 2010 Physical Therapy Continuing Medical Education Course Sponsorship Program 2Health News:North American Seminars Inc. Opens Its 2010 Physical Therapy Continuing Medical Education Course Sponsorship Program 3Health News:North American Seminars Inc. Opens Its 2010 Physical Therapy Continuing Medical Education Course Sponsorship Program 4Health News:Chicken Pox Vaccine May Also Reduce Risk of Shingles Among Children 2Health News:Chicken Pox Vaccine May Also Reduce Risk of Shingles Among Children 3Health News:Cancer Center at Harrington to Begin Seeing Patients 2Health News:Cancer Center at Harrington to Begin Seeing Patients 3Health News:Settlement in AMA Lawsuit against UnitedHealth Gets Preliminary Approval from Federal Court 2Health News:Diabetes Drugs Go Head-to-Head in Study 2Health News:Diabetes Drugs Go Head-to-Head in Study 3Health News:Centegra H1N1 Vaccination Clinics Continue 2Health News:Centegra H1N1 Vaccination Clinics Continue 3Health News:Centegra H1N1 Vaccination Clinics Continue 4
... easy, breezy, beautiful image to its eyewear ... of stylish colors, trendy shapes, spring hinges, ... to target the broad demographics of the ... fashionable frames. The Cover Girl Eyewear collection ...
The license agreement for the manufacturing and distribution of Bulgari eyewear was signed by Luxottica Group in 1997.,Bulgari eyewear is designed for sleek, select people who want to distinguish the...
... The license agreement between Brook Brothers ... 1993. Characterized by lightweight materials and ... collections reflect the unique features of ... A product with classic style and ...
... debuted in 1937 with the Aviator style ... to Luxottica Group's brand portfolio in 1999. ... celebrities since day one, Ray-Bans styles are ... best-selling sunglasses in the world. Characterized by ...
Medicine Products: